The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
 
Jamie Grossman
Employment - Bayer HealthCare Pharmacuticals
Stock and Other Ownership Interests - Bayer HealthCare Pharmacuticals
 
Chistopher Fawsitt
Consulting or Advisory Role - Amicus Therapeutics; Baxter; Bayer HealthCare Pharmacuticals; BMS GmbH & Co. KG; Lundbeck; Merck/Eisai; Pfizer; Roche
 
David Aceituno
Consulting or Advisory Role - Amicus Therapeutics; Baxter; Bayer HealthCare Pharmacuticals; BMS GmbH & Co. KG; Lundbeck; Merck/Eisai; Pfizer; Roche
 
Noman Paracha
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Kirhan Özgürdal
Employment - Bayer HealthCare Pharmacuticals
Stock and Other Ownership Interests - Bayer HealthCare Pharmacuticals
 
Howard Thom
Consulting or Advisory Role - Amicus Therapeutics; Baxter; Bayer HealthCare Pharmacuticals; BMS GmbH & Co. KG; Lundbeck; Merck/Eisai; Pfizer; Roche